Donate For Public and Patients Store Search


2019 Academy advocacy priorities

The advocacy arm of the Academy, the American Academy of Dermatology Association (AADA) provides a voice to dermatologists, ensuring that public policies address the ever-changing needs of practices and patient care. The AADA provides members with valuable resources and tools to adapt to the shifting health care landscape while contributing to policies that protect the quality of and access to dermatologic care.

Advocacy priorities for 2019 include:


Access to Compounded Medications: Guarding against restrictions on board-certified dermatologists’ ability to prepare, administer, and prescribe compounded medications, which is integral to their provision of value-based patient care. Advocating with the Food and Drug Administration (FDA) and the United States Pharmacopoeia (USP) Convention to ensure any guidance or standards, respectively, do not place unreasonable and burdensome restrictions on the practice of medicine and physician-patient relationship. Also includes fighting, as needed, state pharmacy board regulation of physicians preparing compounded medications in the clinical setting.

Learn more about advocacy related to compounding.


Access to Specialty Care through Private and Public Payers: Ensuring adequate and accurate information is available about provider directories for both private and public payers; advocating for appropriate reimbursement for services provided; ensuring that policies within the Medicare program and resulting from implementation of the VA Mission Act, which gives veterans more options to seek care among community providers, facilitate beneficiary access to the full range of specialists including Mohs surgeons, as needed.


Health Care Market Consolidation/Preserving Private Practice: With the current trend toward mergers among health plans, pharmacy benefit managers, etc., and the purchase of practices by private equity firms, health systems and other corporate entities, working to preserve the ability of physicians to own/operate their own practices and maintain competitiveness.


Medicare Physician Payment Policy: Advocating for fair reimbursement under the current fee-for-service program; working across dermatology and within the House of Medicine to preserve the 10- and 90-day global period payments for medical procedures, and in recognition of the challenges implicit with that effort, also working on alternative strategies. Remaining vigilant as the Administration has started taking up some of the limiting strategies of private payers such as prior authorization and reducing payments when E/M services are reported with procedures.


Pharmaceutical Access and Affordability: Working in collaboration with all stakeholders to minimize and/or eliminate barriers that patients face in accessing needed medications, including modifications to step therapy and prior authorization policies as well as efforts to address rising drug prices and drug shortages. Also includes supporting efforts to improve price transparency and to advocate for policies that will encourage competition to lower the cost of medications and improve access to treatment for patients.

Learn more about advocacy related to drug pricing and access.


Scope-of-Practice: Working with all stakeholders to appropriately define the practice of medicine, to ensure a physician-led, team-based approach to care through the adoption or modification of regulations to ensure that, as the workforce expands to include greater use of non-physician clinicians, structures are in place to ensure a focus on the highest level, appropriate care and to ensure patient safety.


Skin Cancer Prevention, Access to Sunscreen and Indoor Tanning: Advocating at the federal and state levels to educate policymakers about skin cancer prevention and detection, and to promote increased regulation of indoor tanning. Working to bridge the interests of sunscreen manufacturers and federal regulators to ensure fair consideration of new sunscreen ingredients based on scientific evidence and demonstration of patient/consumer safety.

Learn more about advocacy related to sunscreen.

Advocacy priorities

Download a PDF version of the 2019 advocacy priorities.

Download priorities

Related Academy resource

Advocacy contacts

Barbara Greenan, Chief Advocacy & Policy Officer
(202) 712-2602

Beth Laws, Director, Director, Advocacy & Policy Operations
(202) 712-2600

Ashley John, Manager, Advocacy & Policy
(202) 609-6332

Federal legislative, political & grassroots advocacy staff:
Shawn Friesen, Director, Legislative, Political and Grassroots
(202) 712-2601

Christine O’Connor, Associate Director, Congressional Policy
(202) 609-6330

Blake McDonald, Manager, Congressional Policy
(202) 712-2608

Michael Giblin, Senior Specialist, Political Affairs
(202) 712-2604

Susie Dumond, Specialist, Grassroots Advocacy & Congressional Affairs
(202) 712-2611

Regulatory & payment policy staff:
Leslie Stein Lloyd, Director, Regulatory & Payment Policy
(202) 712-2614

James Scroggs, Associate Director, Health Economics
(202) 712-2617

David Brewster, Assistant Director, Practice Advocacy
(202) 609-6334

Helen Olkaba, Manager, Health Care Economics
(202) 609-2612

State policy staff:
Lisa Albany, Director, State Policy
(202) 712-2615

Victoria Pasko, Manager, State Policy
(202) 609-6331